<i>Conclusions</i>: In patients with HER2-positive breast cancer treated with pertuzumab-based neoadjuvant therapy, treatment response appears to be primarily influenced by clinicopathological and treatment-related factors rather than systemic inflammatory status. This evidence concerns the gene ERBB2 and breast carcinoma.